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Abstract: This article shows the evolution of the Brazilian legislation in recent years 
in the area of herbal products and discusses the concept of phytotherapy in Brazil, 
bringing information about how it works in Europe.
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 In the last ten years, the Brazilian legislation 
for herbal medicines has evolved a lot in many aspects, 
which was a mandatory precondition to promote us to 
another level, a better level, getting closer to international 
guidelines. We can mention several rules that demonstrate 
clearly such progress, such as the amplifi cation of 
registration forms (herbal medicines registration in Brazil 
has evolved a lot since Ordinance 22/1967 and RDC 
14/2010 currently effective) (Anvisa, 2010), improved 
control of raw material and herbal medicines, creation of 
laws to standardize stability studies (RE 1/2005) (Anvisa, 
2005), guidance to validate analytical and bioanalytical 
methods (RE899/2003) (Anvisa, 2003), guidance to 
perform herbal pre-clinical toxicity studies (RE 90/2004) 
(Anvisa, 2004) and standardized package inserts for herbal 
medicines (RDC 47/09) (Anvisa, 2009). 
 Currently, there are several initiatives on the 
way to continue this evolution process, so we are in a 
regulatory expansion phase for raw materials, creating 
specifi c rules for pharmaceutical herbal raw material, such 
as, Good Practice (CP 63/09) rules, the creation of Good 
Pharmaceutical Practice for medicinal plants and herbal 
drugs, creation of Farmácias Vivas (Living Pharmacies) 
(Ordinance 886/10) (Ministério da Saúde, 2010) and 
Good Practice for medicinal plant and herbal medicine 
processing in Farmácias Vivas (CP 85/10). 
 The initiatives are many, a government movement 
took place in order to stimulate the use of herbal medicines 
in the country and was approved by the National Policy of 
Medicinal Plants and Herbal Medicines - PNPMF (Decree 
5.813/06) (Brasil, 2006) , the approval of the program and 
creation of the National Committee of Medicinal Plants 
and Herbal Medicines (Ordinance 2960/08) (Ministério 
da Saúde, 2008) and the approval of National Policy on 
Integrative and Complementary Practices at the SUS 
(Public Health System) (Ordinance 971/2006) (Ministério 
da Saúde, 2006). 
 In 2009 the Ordinance 2982 was published in 
which the rules have been approved to perform and fi nance 
the Pharmaceutical Care in Primary Care and brings out 
in Attachment II a list of eight herbal and homeopathic 
drugs and in 2010, the national medicinal plant list has 
been disclosed, a list of SUS interests (RENISUS list) 
(Ministério da Saúde, 2009).
 The PNPMF approval, therefore, has motivated 
a series of other regulations and initiatives in a way to 
support the policy and create a technical base in order to 
guide and standardize the herbal medicines in Brazil.  
 In order to continue to mention examples that 
demonstrate this evolving process, we can comment on the 
mobilization of the Brazilian Pharmacopoeia in the sense to 
support the policy and so, several releases were performed 
during 2011 such as the publication of the National Herbal 
Form (RDC 60/11) (Anvisa, 2011), new monographs in 
the Brazilian Pharmacopoeia 5th edition and the Memento 
Brasileiro de Fitoterápicos (Memento of Brazilian Herbal 
Medicines) which is in progress, among others.
 Recently, the Ordinance MS No. 533 was also 
published in March 28th, 2012 which establishes the list of 
drugs and raw materials of the National List of Essential 
Medicines (RENAME) in the Sistema Único de Saúde 
(SUS) scope (Ministério da Saúde, 2012). This ordinance 
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presents in item 88.1, regarding herbal medicines, 
twelve plants species with indications and presentations 
established.
 This cannot be undone and the herbal medicine 
will occupy a bigger space in the Brazilian market in the 
future and we need a regulatory and technical framework 
that allows its future development. Although the search for 
improvement is a continuous process, there is still need 
for further progress and, in some situations, when we take 
a look at the market, we realize that there is no consensus 
regarding the herbal concept. Many people see a herbal 
extract or a herbal medicine the same way they see a 
synthetic one and we know that there is a huge difference 
between these two categories of products.  
 When we talk about Brazilian regulations in the 
herbal segment, it is common to mention the legislation that 
regulates the herbal medicine registration in Brazil (current 
RDC 14/2010) is based on international rules, mainly, 
European rules, where the knowledge on medicinal plants 
and products arising from them are ancient. Regulatory 
bodies are always interested in taking advantage of the 
existing knowledge from other cultures and harmonizing 
the rules, whenever possible.
 Although the concept is not always interpreted 
the same way and in the case with the Brazilian legislation 
some parts are very different. There are some examples 
that can be mentioned, however, it is possible to start with 
the situation described as follows. When the simplified 
registration (RDC 17; RE 89/2000) (Anvisa 2000a,b) was 
created, which has been characterized by an improvement 
process, it started to determine an analytical marker in 
the specification of the extract and the respective dose 
according to such marker. This helped the market a lot 
to improve the quality control, analytical methodologies, 
to standardize extracts (active herbal raw material) and, 
probably, it was the reason to a great revolution in the 
market at the time and it was a great step in improving 
quality. However, as the time passes by, we realize that part 
of the market started to see the extract by its marker and 
what used to be a quality control parameter, was regarded 
as the total quality of the extract.  
 Not that other parameters are being disregarded 
(such as chromatographic profile, ratio herbal drug: extract, 
species variability etc.), but herbal medicines and extracts 
are a complex matrix and when focusing mainly on the 
marker standard the risk is to lose the whole concept.
 In order to improve the analysis of this matter, it 
is important to remember the marker concept that at first 
is about a “compound or compound class of chemicals 
present in the herbal raw material, preferably having a 
correlation with the therapeutic effect and that is used 
both as reference in the herbal raw material quality control 
and in the herbal medicine” - (RDC 14/2010). Therefore, 
the marker is a substance or substance group that can be 
related to the effect, so, they are not necessarily proven 
to be responsible for the activity. Thus, they cannot be 
considered “active ingredients”.
 This way, a mistake can be made when 
determining the medicinal dose according to the marker 
in the simplified registration. When we talk about plants/
herbal drugs there is not always a scientific proof about the 
active ingredient. This information exists for a few plants, 
as for example frângula (anthraquinones), belladona 
(alkaloids), horse chestnut (aescin), sene (sennoside), milk 
thistle (silymarin). There are plants in which a substance 
or a substance class is related to the activity, such as the 
hypericum (hypericin and pseudohypericin) case.
 If we remind ourselves that the herbal drug and 
its derivatives are complex matrixes and with several 
substances interacting with each other in a synergic way, 
all of this makes sense again, i.e., when we talk about 
herbals in most of the time the active ingredient is the total 
extract and not a substance or an isolated fraction.
 It is possible that when getting anxious for better 
control of the materials, desiring more result accuracy and 
better answers in relation to efficacy and product safety, 
was created a distance to the herbal concept and approach 
to regard this as  a synthetic substance, which can create 
big problems for the quality of herbal material.
 Other examples can be shown that lead to this 
path. For instance, the creation of restricted ranges for 
analytical markers in specifications of plant extracts with 
the same severity used for synthetic products, which can 
represent a mistake in a situation that the active constituent 
in unknown. 
 It is necessary to balance the controls and 
parameters to be controlled and/or monitored, taking into 
account the matrix being worked on, i.e., the herbal drug 
as a whole.
 We can also mention, as a complicated matter to 
determine for the same extract two or three markers with a 
restricted range. The plant does not produce substances in 
the same relation and to create this kind of control makes 
the industry work even harder and, at the same time, favors 
the extract adulteration.
 The same thing can be said about the focus on the 
analytical marker instead of the extract in the registration 
process and the extraction process. This is also a situation 
that favors the adulteration and disfavors the control of 
the process, because, most of the times, the quality of the 
extract, in this situation, is measured by the marker and 
not by the composition of the total extract. When it comes 
to active ingredient, this modus operandi makes sense, but 
when it comes to a marker and, normally, aiming only the 
analytical quality control, a severe mistake is made.
 It is important to emphasize the relevance of the 
relation between herbal drug: native extract (the amount 
of native extract = the content of extractable matter) and 
chromatographic profile, both for quality of the extract as 
for the herbal product efficacy, and this does not disqualify 
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the importance of the quantitative analysis of the marker 
that represents an important step in quality control for 
herbal raw materials.
 However, it is known that the less knowledge 
about the therapeutic action of the constituents in herbal 
drugs, the bigger is the need for using qualitative methods 
to evaluate the quality, such as, fingerprint whether by 
TLC or by HPLC.
 Therefore, the first question to be asked is: Is the 
active constituent known or not? Since we do not know 
it in the majority of the cases, the whole extract will be 
regarded as the active ingredient. 
 One of the most important parameters to be 
observed in the extract is its composition (native extract 
content that represents the extract without excipients) and 
the  DER native (Drug Extraction Ratio native), in addition 
to all items that compose the specification of the product 
such as extraction solvent and raw material quality, as well 
as the manufacture process, taking into account that it must 
be validated.  
 As the majority of the existing products in the 
market are approved by simplified registration and points 
score registration, therefore, the traditional use is based on 
plants or extracts mentioned in official literatures, when 
changing focus in some products to mainly analytical 
marker standards, it is possible to lose these references 
and the efficacy matter can be jeopardized. The simplified 
product registration and all other registration forms, always 
indicates daily dosage based on analytical marker content. 
This is usually not and adequate way and can provide 
wrong dosage of genuine extract. For both the “quantified 
and other” extracts categories, the active substance is the 
genuine extract and dosage should always be established 
in active substance. 
 Thus, all these matters were mentioned and one 
question can be asked: do you think the phytotherapy 
concept the way it is being worked in Brazil could not 
be aligned to the one practiced internationally? In order 
to complete this analysis, the following paragraphs will 
provide information about the phytotherapy concept in 
Europe and how the extracts are classified. 
Concepts in Europe
 DER native is the ratio between herbal drug and 
genuine extract (extract without excipients). Therefore, 
the DER native is the amount of material that can be 
extracted (dry residue - extractable matter) that is obtained 
with a proper extraction solvent and a validated extraction 
process. There is also in the European literature the DER 
concept (without the word “native”) and in this case, it is 
about the ratio between the herbal drug (raw material) and 
the extract (finished product/ non native extract). However, 
the most developed amount is of DER native, because it is 
related to the plant proportion in relation to the genuine 
extract.
Extract classification
 In Europe, the extracts are classified in three 
forms, according to the European Pharmacopoeia 7.6 
edition (EP, 2012) and Herbal Medicinal Products (Gaedke 
& Steinhoff, 2003):
 Standardized extracts
 Extracts in which compounds have known 
therapeutic activity (active). In this type, the amount of 
native extract (genuine) is variable. The native or genuine 
extract is the extract without excipients. The extract is 
adjusted within the range defined for the active. Adjustment 
is carried out with inert excipients or by blending of 
production batches with a higher or lower content of 
therapeutically active constituents, resulting in a variable 
amount of native herbal drug preparation (native extract). 
Ex. belladonna
 Quantified extracts
 Extract adjusted within a defined range of 
compounds, which relation with the activity is proved 
through clinical trials. Therefore, the compounds are 
generally accepted to contribute to the therapeutic activity. 
They are known as active markers. In this type, the amount 
of native extract (genuine) is constant. Adjustment can only 
be achieved by blending of batches of extracts with the 
same specification and on the basis of a constant amount 
of native herbal extract. Ex. Ginkgo biloba.
 Other extracts
 These extracts are mainly defined by their 
manufacturing process (state of the drug to be extracted, 
solvent, extraction conditions) as well as their specification. 
In this case the active substance is the native extract and 
the amount of native extract is constant. There is no 
adjustment for a constituent or group of constituents. In 
this type, the constituents with known therapeutic activity 
or active markers (which are related to the activity) are not 
known. There is indication of the analytical markers and 
in this case the contents are batch-specific, informative, or 
it is recommended to have a minimum content referred to. 
Ex. valerian.
 Existing monographs in the European 
Pharmacopoeia - current edition is possible to confirm 
this classification not only in "Extracts" found in "General 
Monographs", but also in the titles of monographs. 
 The monographs whose extracts are classified 
as Standardized have this word in the title, the same 
occurs for the monographs whose extracts are classified 
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as Quantified, as in the case of titles where there is no 
mention of the classification, they belong to Other.
 Thus, out of the 43 extracts with monographs 
in the European Pharmacopoeia Edition 7.6, it can be 
observed the existence of fifteen extracts classified as 
Standardized and four extracts classified as Quantified. 
The others would be considered as Other.  
 Within this classification and from my point 
of view, we can say that many of the plants and market 
extracts fit in the second and third classes (possibly the 
major part in the third class), since the active principle 
(recognized as responsible for the therapeutic activity) or 
active marker (activity related substances) is not always 
known. 
 As information, there is a guide (Guideline on 
declaration of Herbal Substances and Herbal Preparations 
in herbal medicinal products/traditional herbal medicinal 
products) of European Medicines Agency (EMA, 2010), 
where rules are established for the labeling of these 
products according to the classification of the extract. And 
in case of Other Extracts class, it is not allowed to declare 
on the label the name and content of the marker (analytical 
marker).
 Charter 1 summarizes the classification of 
the extracts into categories, which, particularly, I find 
it very interesting and easier to understand. From this 
classification, we might reflect on its application within 
the concept of herbal raw materials and herbal medicines 
in Brazil.
 A standardization of an extract in Europe is related 
to the therapeutic activity of the relevant constituents. In 
most cases, in Other extracts and Quantified Extracts, 
the native extract (= extractable matter) is considered  the 
active ingredient. Consequently, the composition of the 
extract (ratio of the native extract: excipients) is fixed, 
having the same proportion of native extract for each 
batch (for example, extract 80% native extract). Only the 
Standardized Extract having constituents with proven 
therapeutic activity are adjusted for these constituents. As 
a result, the native extract : excipients ratio is variable.
 In Brazil, not always the standardization of the 
extracts is related to the therapeutic activity of the relevant 
constituents. Standardization provides ranges for the 
markers regardless of their contribution to the therapeutic 
activity. As a result, the proportion of native extract (extract 
without excipients) is always variable.
 It is important to emphasize that presenting a 
range for the active ingredient and dosage on the basis 
of this is not what is being questioned, because in this 
case (Standardized Extract) it is proven that sustenance 
is responsible for the effect. Within this, mandatorily the 
amount of native extract is variable (it is not possible to 
create a range for the amount of active ingredient with a 
constant quantity of native extract) and the active content 
will be constant within the range established as mentioned 
in the table above (adjusted with excipients or with a 
blending of batches of extracts).
 In case of Quantified extracts, a range is allowed, 
though related to clinical trials (and therefore studies that 
confirm the relationship of that substance with the activity). 
As discussed before, in this scenario the amount of native 
extract is also constant. For achieving the batch to batch 
consistency within establish ranges for marker standard(s) 
is only permitted blending of batches, because only in this 
way keeps the composition of native extract constant.
 For extracts classified as “Other” the amount of 
native extract in final extract composition is fixed and thus 
nor blending or adjustment with excipients is permitted. By 
this, marker standard is either batch specific or as normally 
established by a minimum content. If establishing range for 
“other” extracts, the amount of native extract (extractable 
matter) will be affected and hence the efficacy of the 
Charter 1. Classification of extracts.
Assessment Extract concept
Extract adjustment Extract typePharmacological/therapeutic 
relevance
Amount
Marker Native extract
Constituents with known 
therapeutic activity
Constituents with known 
therapeutic activity 
Constant
Variable 1. inner carrier material 
2. blending of batches
Standardised
Constituents which are 
generally accepted to 
contribute to the known 
therapeutic activity
Active marker 
Range1
Constant Blending of batches Quantified 
(pharmacol/clinically 
tested extract)
Constituents with known 
therapeutic activity or 
active markers of the herbal 
substance/preparation are not 
known
Analytical marker 
Variable 
(min content if appropriate)
Constant None Other
Source: Regulatory Department SaRA- Finzelberg GmbH & Co.Kg.
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extract.  
 Thus, the question discussed in this article is 
the fact that in most cases, they talk about a marker and 
no active ingredient, therefore, the decisive question to 
be asked is: What is the type of extract (classification) 
i.e., is the active ingredient known or not? And so, this 
classification would determine the features of this extract 
and how it can be worked into the final product.
 These concepts related to classification of the 
extracts are still discussed in Europe and there are forums 
that take place periodically to discuss improvements and 
optimizations, however it is worth knowing and assessing 
their relevance to our reality.
 In Europe, the DER native is also necessary to 
inform for calculating the daily dose of the extract. So 
this determination is not based on the substance alone, but 
also in the relationship between herbal drugs and genuine 
extract (native extract).
 The purpose of this paper is to contribute with 
information about the concept of herbal medicine in 
Europe and perceptions of how we have worked in Brazil 
and then after assessing, try to get the best parts of the 
concept and adapted in our legislation.  
 The interest is in allowing our market to have 
herbal medicines containing extracts consistent with the 
literature data and, consequently, the expected effectiveness 
and safety.
 Currently these concepts are already being 
discussed in Brazil and the objective here is to disseminate 
this information so that there is an understanding of how 
it works out in Europe and the possibility to redeem these 
concepts for improving to the way that these concepts are 
being handled today.  
 As a conclusion, it is important to remember  that, 
even if  the literatures and scientific papers are being used for 
the registration of herbal medicines, this is based on external 
knowledge and big part of this is derived  from Europe. 
We also need to understand these concepts and external 
assess and consider whether these concepts are suitable for 
the Brazilian market; since they take into accout different 
categories of extracts relating the chemical constituents and 
therapeutic activity and all are based on extract as active 
material.
 Brazil have shown a big evolution over its 
production of scientific papers these recent years, but 
currently we still don´t have enough   information about 
Brazilian herbal drugs and extracts for product registration 
purposes.  This scenario might certainly change in the 
future, however it takes a long time to build this up. 
 It is worth saying that my perception is that 
ANVISA and especially the groups that deal with the 
registration of herbal medicine are open to discussions and 
at the same time seeking to harmonize knowledge, which 
is very important.
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